Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model
Authors:
- 1 August 2019
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 15 (9) , 1133-1148
Abstract
Introduction: Immunotherapeutic approaches targeting amyloid β (Aβ) protein and tau in Alzheimer's disease and α‐synuclein (α‐syn) in Parkinson's disease are being developed for treating dementia with Lewy bodies. However, it is unknown if single or combined immunotherapies targeting Aβ and/or α‐syn may be effective.Methods: Amyloid precursor protein/α‐syn tg mice were immunized with AFFITOPEs® (AFF) peptides specific to Aβ (AD02) or α‐syn (PD‐AFF1) and the combination.Results: AD02 more effectively reduced Aβ and pTau burden; however, the combination exhibited some additive effects. Both AD02 and PD‐AFF1 effectively reduced α‐syn, ameliorated degeneration of pyramidal neurons, and reduced neuroinflammation. PD‐AFF1 more effectively ameliorated cholinergic and dopaminergic fiber loss; the combined immunization displayed additive effects. AD02 more effectively improved buried pellet test behavior, whereas PD‐AFF1 more effectively improved horizontal beam test; the combined immunization displayed additive effects.Discussion: Specific active immunotherapy targeting Aβ and/or α‐syn may be of potential interest for the treatment of dementia with Lewy bodies.Keywords
Funding Information
- NIH (AG18840, BX003040, AG0051839, AG10483, AG005131)
This publication has 97 references indexed in Scilit:
- RETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease PathophysiologyJournal of Neuroscience, 2012
- Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's diseaseBMC Neuroscience, 2011
- Assessment of α-Synuclein Secretion in Mouse and Human Brain ParenchymaPLOS ONE, 2011
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body DiseasePLOS ONE, 2011
- Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive DeclineThe Journal of Neuroscience, 2010
- Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic FactorsThe Journal of Neuroscience, 2010
- Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-SynucleinopathyPLOS ONE, 2010
- Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's diseaseNeurobiology of Disease, 2009
- Immunization with Amyloid-β Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse ModelJournal of Neuroscience, 2009
- Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's DiseasesPLOS ONE, 2008